March 31, 2025
Last week; equities sold-off and during most of March, February and January; this week will the cell and gene therapy sector be liberated not likely?
Pre-empted by a weak pre-open and aftermarket after all the past 3 months downslides
Pre-Open Indications: 4 Negative Indications
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief …
I am NOT often wrong and always consider doubt of some market and sector share pricing movements
Never leave an investor uninform
April 1, 2025
From and continued, "The clock continues to tick down on Harvard Apparatus GT (OTCQB: HRGN)
In FY24, OTCQB: HRGN net loss was -$7.73 M or -$0.52 per share with a cash position of $2.5 M with a runway until Q2/25.
Accumulated deficit of $99.7 M
Liabilities $1,220 M while (in addition) still owing accounts payable: Un. of Pittsburg -$130 K, Yale University -$61 K and former employees $133 k
Product Development: (from 10K, 3/31/25)
April 1, 2025
Indexes are mixed so what is the market pricing-in?
Tuesday, the CBOE Volatility Index (VIX) closed at 21.77 after Monday’s 22.28; the VIX got as high as 24.80, eclipsing Friday’s high of 22.18, before closing at 21.65.
I say today what others won't, so you can do what others can't!
Never leave an investor uninformed!
April 1, 2025
From and continued, "The clock continues to tick down on Harvard Apparatus GT (OTCQB: HRGN) In FY24, OTCQB: HRGN net loss was -$7.73 M or -$0.52 per share with a cash position of $2.5 M with a runway until Q2/25. Accumulated deficit of $99.7 M Liabilities $1,220 M while (in addition) still owing accounts payable: Un. of Pittsburg -$130 K, Yale University -$61 K and former employees $133 k Product Development: (from 10K, 3/31/25) Our first esophageal product candidate, our esophageal implant was used in the first successful regeneration of the esophagus in a patient with esophageal cancer. This successful first-in-human experience, plus the research we have performed on over 50 pigs, led the FDA to approve our 10-patient phase 1 clinical trial. This combination trial will measure both safety and efficacy in the patient population. “We have encountered delays in patient recruitment for our ongoing clinical trial, driven by several factors, including the existing comorbid conditions for clinical trial participants, the stringent eligibility criteria required by FDA for our studies, and logistical difficulties in enrolling participants across various sites.” “Although we are actively implementing strategies to mitigate these challenges, such as increasing the number of trial sites and enhancing patient outreach efforts, there is a risk that these measures may not completely resolve the recruitment issues. Our product candidates are currently in development and have not yet received regulatory approval for sale anywhere in the world.”
March 10, 2025
including pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant with an exercise price of $0.01 per share. BEAM closed Friday at $1.23 to $28.48 with a pre-open indication of $2.57 or +0.02% to $31.05 Gross proceeds from the offering are expected to be approximately $500.0 million expected to close on or about 3/11/2525
February 18, 2025
35.739 M shares were priced at $4.30 with 13.88 M warrants priced at $4.029 Tuesday SLDB jumped +$1.27 to $5.30 The financing includes new and existing investors, including Adage Capital Partners LP, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital Management, TCGX, Venrock Healthcare Capital Partners, Vestal Point Capital, a U.S.-based life-sciences focused institutional investor, a major mutual fund and a large investment management firm.
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
